In a randomized phase 2 study in non–small cell lung cancer, the anti-CD73 Ab oleclumab in combination with anti-PD-L1 agent durvalumab provided a significant improvement in progression-free survival over durvalumab alone (hazard ratio, 0.44) (26). Here, NT5E is linked to lung cancer.